HTA requirements and evidence standards vary by country and evolve quickly, turning market access expansion into a moving target.
Bridging an HTA dossier across markets is no longer just reformatting: it requires re-validating claims, aligning to local methodological expectations, and updating comparators, endpoints, and value narratives.
With evidence scattered across clinical, HEOR, RWE, and prior submissions, maintaining consistency, traceability, and speed across adaptations is a major challenge.
6× faster country adaptations
Accelerate country-specific HTA adaptations by producing localized gap maps, evidence tables, and value narratives from a shared clinical, HEOR, and RWE evidence base.
Fewer internal review loops
Reduce internal back-and-forth by aligning comparators, endpoints, local methods, payer expectations, and value story changes before drafting country-specific submissions.
Stronger, traceable value story
Build localized value narratives with every claim linked to source evidence, assumptions, comparators, endpoints, and country-specific methodological requirements.
How it works
1
Assemble the HTA reference corpus — centralize country-specific HTA methods, submission templates, and payer expectations (HAS, NICE, G-BA, etc.) as a governed, versioned baseline.
2
Define the bridging context — select target countries, indication, comparators, population, outcomes, and evidence sources; Biolevate builds an “applicability map” of what changes market-to-market.
3
Run an exhaustive gap & adaptation analysis — compare the source dossier against each country’s requirements to identify missing sections, required reframing, evidence gaps, and local appendix needs with full traceability.
4
Generate guided rewrites and localized drafts — produce country-aligned updates (value story, clinical evidence narrative, economic sections, evidence tables) with source-linked claims and a run record for review and reuse.
Country-specific gap mapping: compare a source dossier against local HTA methods, templates, comparators, endpoints, and evidence expectations with a full run record.
Shared evidence base localization: reuse one governed evidence base to generate country-specific narratives, tables, and adaptation rationale across Market Access, HEOR, and Pricing teams.